HYDERABAD, India--(뉴스와이어) 2019년 07월 11일 -- GVK BIO is pleased to announce the appointment of Dr. Robert (Bob) R. Ruffolo, to its Board of Directors.
“On behalf of GVK BIO and its Board of Directors, I am pleased to welcome Dr. Robert Ruffolo to the Board,” stated Davinder Singh Brar, Chairman GVK BIO. “With a career spanning over four decades in the Pharmaceutical industry, Bob is an accomplished leader with a rare blend of scientific expertise, strategic thought and commercial acumen.”
“I am excited to join the GVK BIO Board,” added Dr. Bob Ruffolo. “With a talented pool of scientists, integrated capabilities, and a ‘customer first’ culture, GVK BIO is ideally positioned to benefit from the growing industry trend to establish preferred external partnerships to drive Research and Innovation. I look forward to working with the team and establishing the company as a ‘Partner of Choice’ in the Pharmaceutical sector.”
Dr. Ruffolo served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Bob was Senior Vice President in R&D at SmithKline Beecham Pharmaceuticals (now GSK) for 17 years. Bob played a significant role in the discovery and/or development of a number of marketed products, including carvedilol, ropinerole, dobutamine, and eprosartan, among others. He has been recognised with several prestigious awards, including the Discoverer's Award in 2008, for his pioneering work on the discovery of carvedilol for the treatment of congestive heart failure. Bob currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics and Aridis Pharmaceuticals. He is also the President of Ruffolo Consulting LLC, a position he has held since 2008.
Dr. Ruffolo holds a B.S. degree in Pharmacy, and a Ph.D. degree in Pharmacology, both from The Ohio State University.
About GVK BIO
GVK BIO, a Contract Research & Development Organization that services the global Pharmaceutical industry is headquartered in Hyderabad, India and has five sites across the globe. Established in 2001, GVK BIO serves large and small pharma clients across the R&D value chain with a focus on speed and quality, ensuring safety and compliance. GVK BIO’s team of over 2200 scientists, are supported by a no-conflict business model, modern facilities, strong customer-centric culture, and focus on bringing their customers products to market rapidly and cost effectively.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005266/en/